Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S257000, C514S277000, C514S279000
Reexamination Certificate
active
07910586
ABSTRACT:
The present invention provides methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate Aβ levels. The invention also provides modulation of Aβ levels via selective modulation (e.g., inhibition) of ATP-dependent γ-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a modulator of γ-secretase, including, but not limited to, a selective inhibitor of ATP-dependent γ-secretase activity or an agent that decreases the formation of active (or optimally active) γ-secretase. The invention also provides the use of inhibitors of ATP-dependent γ-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.
REFERENCES:
patent: 5272055 (1993-12-01), Haley
patent: 5385915 (1995-01-01), Buxbaum et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5543520 (1996-08-01), Zimmermann
patent: 5733914 (1998-03-01), Blankley et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6147073 (2000-11-01), Battistini et al.
patent: 6451838 (2002-09-01), Moon et al.
patent: 2002/0025540 (2002-02-01), Roberts et al.
patent: 2002/0128319 (2002-09-01), Koo et al.
patent: 2002/0147197 (2002-10-01), Newman et al.
patent: 0949242 (1999-10-01), None
patent: WO 96/34867 (1996-11-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/19305 (1999-04-01), None
patent: WO 01/64200 (2001-09-01), None
patent: WO 01/77086 (2001-10-01), None
patent: WO 01/78721 (2001-10-01), None
patent: WO 01/85924 (2001-11-01), None
patent: PCT/US03/00249 (2003-01-01), None
Borchelt, et al., “Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate Aβ1-42/1-40 Ratio in Vitro and in Vivo,”Neuron.(1996) 17: 1005-1013.
DeMattos, et al, “Peripheral anti-Aβ Antibody Alters CNS and Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mosue Model of Alzheimer's Disease,”PNAS(2001) 98(15): 8850-8855.
Dou, et al., “Chaperones Increase Association of the Tau Protein with Microtubules,”Proc. Natl Acad SciUSA (2003) 100(2): 721-726-12449.
Durkin, et al., “Rank-Order of Potencies for Inhibition of the Secretion of Aβ40 and Aβ42 Suggests That Both Are Generated by a Single γ-Secretase,”The Journal of Biochemistry(1999) 274(29): 20499-20504.
De Strooper, et al., “A Presenilin-l-Depenedent γ-Secretase-Like Protease Mediates Release of Notch Intracelllular Domain,”Nature(1999) 398: 518-522.
Esler, et al., “Transition-State Analogue Inhibitors of γ-Secretase Bind Directly to Presenilin-1,”Nature Cell Biology(2000) 2: 428-434.
Gasparini, et al., “Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling,”The Journal of Neuroscience(2001) 21(8): 2561-2570.
Moasser, et al., “Inhibition of Src Kinases by a Selective Tyrosine Kinase Inhibitor Causes Mitotic Arrest,”Cancer Research(1999) 59: 6145-6152.
Nagar, et al., “Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571),”Cancer Research(2002) 62: 4236-4243.
Netzer, et al., “Gleevec Inhibits Beta-Amyloid Production but not Notch Cleavage.,”Proc. Natl Acad Sci USA(2003) 100(21): 12444-12449.
Petanceska, et al., “The Phosphatidylinositol 3-Kinase Inhibitor Wortmannin Alters the Metabolism of the Alzheimer's Amyloid Precursor Protein,”Journal of Neurochemistry(1999) 73(6): 2316-2320.
Schindler, et al., “Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase,”Journal of Neurochemistry(2000) 289: 1938-1942.
Selkoe, Dennis J., “Deciphering the Genesis and Fate of Amyloid β-Protein Yields Novel Therapies fro Alzheimer Disease,”Journal of Neurochemistry(1999) 73(6): 2316-2320.
Vandermeeren, et al., “The Functional γ-Secretase Inhibitor Prevents Production of Amyloid β 1-34 in Human and Murine Cell Lines,”Neuroscience Letters.(2001) 315: 145-148.
Wolfe, Michael S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential,”Journal of Medicinal Chemistry(2001) 44(13): 2039-2060.
Xu, et al., “Generation of Alzheimer β-Amyloid Protein in the Trans-Golgi Network in the Apparent Absence of Vesicle Formation,”Proc. Natl. Acad. Sci(1997) 94: 3748-3752.
Zhang, et al., “Biochemical Characterization of the γ-Secretase Activity That Produces β-Amyloid Peptides,”Biochemistry(2001) 40: 5049-5055.
Esler, W.P., et al.A Portrait of Alzheimer Secretases—New Features and Familiar Faces, Science, 2001, pp. 1449-1454, vol. 293.
Selkoe, D.J.Alzheimer's Disease: Genotypes, Phenotype, and Treatments, Science, 1997, p. 630, vol. 275.
Vassar, R., et al. β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, Science, 1999, pp. 735-741, vol. 286.
Schenk, D., et al.Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse, Nature, 1999, pp. 173-177, vol. 400.
Netzer, W.J., et al.Gleevec Inhibits β-Amyloid Production But Not Notch Cleavage, PNAS, 2003, pp. 12444-12449, vol. 100.
Gilman, S., et al.Clinical effects of Aβ Immunization (AN1792) in Patients with AD in an Interrupted Trial, Neurology, 2005, pp. 1553-1562, vol. 64.
Dominguez et al., Secretase as therapeutic targets for the treatment of Alzheimer's disease, Amyloid: J. Protein Folding Disord. 8, 124-142(2001).
Dumont et al., Synthesis and Study of the Anti-Leukaemic Activity of N,N′-Substituted Amidines and Bis-Amidines, J. Pharm. Belg., 40:6, 373-386 (1985).
Goodwin, et al., P3-215: Inhibition of gamma-secretase activity induces cell cycle defects and chromosome missegregation, Alzheimer's & Dementia, vol. 4, No. 1, p. T614 Jul. 1, 2008.
Kraker et al., Biochemical and Cellular Effects of c-Src Kinase-Selective Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors, Biochemical Pharmacology, vol. 60, pp. 885-898 (2000).
Williamson et al., Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-B Peptide Exposure: Involvement of Src Family Protein Kinases, J. of Neuroscience, 22(1):10-20 (Jan. 1, 2002).
Wolfe, M., γ-Secretase Inhibitors as Molecular Probes of Presenilin Function, J. Mol. Neuroscience, vol. 17, pp. 199-204 (2001).
Greengard Paul
Netzer William
Xu Huaxi
Chong Yong S
Hoxie & Associates LLC
The Rockefeller University
LandOfFree
Compositions and methods for prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684398